180 Wealth Advisors LLC Raises Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

180 Wealth Advisors LLC boosted its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 18.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,167 shares of the company’s stock after purchasing an additional 803 shares during the period. 180 Wealth Advisors LLC’s holdings in CRISPR Therapeutics were worth $203,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. State Street Corp increased its stake in CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after purchasing an additional 599,304 shares in the last quarter. FMR LLC increased its stake in CRISPR Therapeutics by 1.0% in the 3rd quarter. FMR LLC now owns 2,376,166 shares of the company’s stock valued at $111,632,000 after purchasing an additional 23,075 shares in the last quarter. Geode Capital Management LLC increased its stake in CRISPR Therapeutics by 3.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after purchasing an additional 35,196 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in CRISPR Therapeutics by 2.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 950,149 shares of the company’s stock valued at $51,326,000 after purchasing an additional 19,094 shares in the last quarter. Finally, Baker BROS. Advisors LP increased its stake in CRISPR Therapeutics by 743.1% in the 3rd quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock valued at $39,608,000 after purchasing an additional 743,075 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Needham & Company LLC reissued a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday. Chardan Capital reissued a “buy” rating and set a $94.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. JMP Securities reissued a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Finally, Bank of America dropped their price target on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $78.38.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares in the company, valued at $10,002,854. The trade was a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Trading Up 1.8 %

Shares of CRISPR Therapeutics stock opened at $39.04 on Thursday. CRISPR Therapeutics AG has a twelve month low of $36.52 and a twelve month high of $91.10. The stock has a market capitalization of $3.33 billion, a P/E ratio of -13.80 and a beta of 1.62. The business’s fifty day moving average price is $45.46 and its 200 day moving average price is $48.30.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. The firm had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same quarter last year, the firm earned ($1.41) earnings per share. As a group, sell-side analysts predict that CRISPR Therapeutics AG will post -5.13 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.